NO20062081L - Fremgangsmate - Google Patents
FremgangsmateInfo
- Publication number
- NO20062081L NO20062081L NO20062081A NO20062081A NO20062081L NO 20062081 L NO20062081 L NO 20062081L NO 20062081 A NO20062081 A NO 20062081A NO 20062081 A NO20062081 A NO 20062081A NO 20062081 L NO20062081 L NO 20062081L
- Authority
- NO
- Norway
- Prior art keywords
- immunization
- administration
- patient
- cell epitope
- days
- Prior art date
Links
- 230000003053 immunization Effects 0.000 abstract 4
- 238000002649 immunization Methods 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000005867 T cell response Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Oppfinnelsen omhandler en fremgangsmåte for å fremkalle en T-cellerespons mot en T-celleepitope i en vertspattedyrpasient, hvor fremgangsmåten omfatter: (i) en første immunisering omfattende minst to administreringer med fra 1 til 14 dagers mellomrom, til pasienten, hvori hver administrering omfatter å administrere et nukleotid av interesse (NOI) som koder for T-celleepitopen, og alternativt (ii) en andre imunisering omfattende minst en administrering til pasienten av (a) en NOI som koder for T-celleepitopen, eller (b) et protein omfattende T-celleepitopen,. hvor tiden mellom. - den første andministreringen av den første immuseringen, og. - den første andministreringen av den andre immuseringen,. er fra 21 til 365 dager.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51008603P | 2003-10-10 | 2003-10-10 | |
US52657103P | 2003-12-04 | 2003-12-04 | |
US56777104P | 2004-05-05 | 2004-05-05 | |
PCT/US2004/033391 WO2005035779A2 (en) | 2003-10-10 | 2004-10-12 | Method |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062081L true NO20062081L (no) | 2006-06-20 |
Family
ID=34437668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062081A NO20062081L (no) | 2003-10-10 | 2006-05-09 | Fremgangsmate |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070026015A1 (no) |
EP (1) | EP1675596A4 (no) |
JP (1) | JP2007508319A (no) |
KR (1) | KR20060123138A (no) |
CN (1) | CN1889963A (no) |
AU (1) | AU2004280630A1 (no) |
BR (1) | BRPI0415202A (no) |
CA (1) | CA2542295A1 (no) |
EA (1) | EA012066B1 (no) |
IL (1) | IL174849A0 (no) |
MX (1) | MXPA06003977A (no) |
NO (1) | NO20062081L (no) |
NZ (1) | NZ547042A (no) |
SG (1) | SG146662A1 (no) |
WO (1) | WO2005035779A2 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0415204A (pt) | 2003-10-10 | 2006-12-05 | Powderject Vaccines Inc | construção de ácido nucleico, métodos de obtenção da expressão em células de mamìferos de um polipeptìdeo de interesse, e de imunização com ácido nucleico, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìculas, dispositivo de liberação mediada por partìculas, e, sequência de promotor quimérico isolada purificada |
US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
NZ564243A (en) | 2005-06-08 | 2011-03-31 | Dana Farber Cancer Inst Inc | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway |
ES2370040T3 (es) * | 2005-10-07 | 2011-12-12 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Vacuna de metaloproteinasa 11 de la matriz. |
WO2008011609A2 (en) * | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
WO2008083174A2 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2009127666A2 (en) * | 2008-04-15 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Method and compositions |
AU2009319701B2 (en) | 2008-11-28 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods for the treatment of infections and tumors |
RU2542435C2 (ru) * | 2009-03-24 | 2015-02-20 | Трансжене Са | Биомаркер для мониторинга пациентов |
EP2970871A4 (en) * | 2013-03-15 | 2016-08-31 | Univ Rush Medical Center | PSEUDOMONAS EXOTOXINS FOR THE TREATMENT OF CANCER |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
EP3294326B1 (en) | 2015-05-15 | 2021-04-21 | CureVac AG | Prime-boost regimens involving administration of at least one mrna construct |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US6183746B1 (en) * | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
AU765940B2 (en) * | 1998-06-24 | 2003-10-02 | Innogenetics N.V. | Particles of HCV envelope proteins: use for vaccination |
BR0012740A (pt) * | 1999-07-12 | 2002-05-28 | Genesis Res & Dev Corp Ltd | Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego |
AU2001283094A1 (en) * | 2000-08-07 | 2002-02-18 | Sloan-Kettering Institute For Cancer Research | Method and composition for immunization using mixed pools of mutated nucleic acids or peptides |
WO2002024232A2 (en) * | 2000-09-25 | 2002-03-28 | Board Of Regents, The University Of Texas System | Pei: dna vector formulations for in vitro and in vivo gene delivery |
GB0206461D0 (en) * | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
AU2003216852B2 (en) * | 2002-03-19 | 2008-09-11 | Glaxo Group Limited | Imidazoquinolineamines as adjuvants in HIV DNA vaccination |
US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
WO2003080114A2 (en) * | 2002-03-19 | 2003-10-02 | Powdermed Limited | Imidazoquinoline adjuvants for vaccines |
-
2004
- 2004-10-12 MX MXPA06003977A patent/MXPA06003977A/es not_active Application Discontinuation
- 2004-10-12 SG SG200806935-3A patent/SG146662A1/en unknown
- 2004-10-12 CN CNA2004800364591A patent/CN1889963A/zh active Pending
- 2004-10-12 US US10/574,922 patent/US20070026015A1/en not_active Abandoned
- 2004-10-12 BR BRPI0415202-6A patent/BRPI0415202A/pt not_active IP Right Cessation
- 2004-10-12 JP JP2006534429A patent/JP2007508319A/ja not_active Withdrawn
- 2004-10-12 EA EA200600738A patent/EA012066B1/ru not_active IP Right Cessation
- 2004-10-12 EP EP04794672A patent/EP1675596A4/en not_active Withdrawn
- 2004-10-12 AU AU2004280630A patent/AU2004280630A1/en not_active Abandoned
- 2004-10-12 NZ NZ547042A patent/NZ547042A/en unknown
- 2004-10-12 CA CA002542295A patent/CA2542295A1/en not_active Abandoned
- 2004-10-12 KR KR1020067009022A patent/KR20060123138A/ko not_active Application Discontinuation
- 2004-10-12 WO PCT/US2004/033391 patent/WO2005035779A2/en active Application Filing
-
2006
- 2006-04-06 IL IL174849A patent/IL174849A0/en unknown
- 2006-05-09 NO NO20062081A patent/NO20062081L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ547042A (en) | 2010-05-28 |
KR20060123138A (ko) | 2006-12-01 |
WO2005035779A2 (en) | 2005-04-21 |
CN1889963A (zh) | 2007-01-03 |
AU2004280630A1 (en) | 2005-04-21 |
IL174849A0 (en) | 2008-02-09 |
EA012066B1 (ru) | 2009-08-28 |
JP2007508319A (ja) | 2007-04-05 |
MXPA06003977A (es) | 2006-06-27 |
CA2542295A1 (en) | 2005-04-21 |
WO2005035779A3 (en) | 2005-07-14 |
SG146662A1 (en) | 2008-10-30 |
EA200600738A1 (ru) | 2006-10-27 |
EP1675596A2 (en) | 2006-07-05 |
US20070026015A1 (en) | 2007-02-01 |
BRPI0415202A (pt) | 2006-12-05 |
EP1675596A4 (en) | 2009-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062081L (no) | Fremgangsmate | |
NO20091665L (no) | Tumorassosierte antigenderivater fra MAGE-familien, og nuklinsyresekvenser som koder for disse, anvendt for fremstilling av fusjonsproteiner og for vaksinesammensetninger | |
DK1185691T3 (da) | Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf | |
DK0853487T3 (da) | Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus | |
ATE231002T1 (de) | Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus | |
MXPA01003557A (es) | Secuencias genomicas de neisseria y metodos para su uso. | |
BR0315228A (pt) | vacinas de polipeptìdeo para ampla proteção contra linhagens meningocócicas hipervirulentas | |
HUP0402048A2 (hu) | Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására | |
NO341586B1 (no) | Fremgangsmåte for valg av et anti-naturlig drepe cellereseptor (NKR) antistoff | |
DE69929444D1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
AU2003244855A1 (en) | Method to enhance an immune response of nucleic acid vaccination | |
ES8801319A1 (es) | Un metodo para la deteccion de anticuerpos especificos de un virus lav en un fluido biologico. | |
NO20026121L (no) | Streptokokkantigener | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
DE69939747D1 (de) | Verfahren von dna-impfung | |
WO2002033116A3 (en) | Nucleic acid ligands to the prostate specific membrane antigen | |
DK0880360T3 (da) | Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop | |
ES2177927T3 (es) | Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico. | |
Lu et al. | Novel vaccine design based on genomics data analysis: A review | |
ATE206138T1 (de) | Helicobacter pylori antigen | |
McDaniel et al. | A physician’s guide to the 2-dose schedule of MenB-FHbp vaccine | |
DE60021409D1 (de) | Neurokinin b vorläufer aus menschlicher plazenta | |
AU2579600A (en) | Product and method for obtaining specific immunisation with one or more antigens | |
NO970701L (no) | Vaksiner inneholdende Borrelia burgdorferi OspG | |
WO2002085409A3 (en) | Methods and compositions for inducing an immune response to an antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |